Molecular diagnostics

Biocept Reaches COVID-19 Testing Milestone with More than 7,000 Specimens Received and More than 6,500 Specimens Processed

Monday, August 3, 2020 - 1:00pm

The vast majority of COVID-19 test results were reported to healthcare providers within 48 hours of receipt of the specimen.

Key Points: 
  • The vast majority of COVID-19 test results were reported to healthcare providers within 48 hours of receipt of the specimen.
  • "We are proud to reach this milestone and to serve our community by providing highly accurate PCR-based COVID-19 diagnostic testing with a quick turnaround time," said Michael Nall, President and CEO of Biocept.
  • "We are fortunate to have highly qualified and dedicated laboratory technicians, cutting-edge testing instrumentation, and an increasing supply of collection kits," he added.
  • Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.

Co-Diagnostics, Inc. Technology to be Used in FDA-Authorized Self-Collected COVID-19 Saliva Test

Monday, August 3, 2020 - 11:30am

According to CRL's announcement , Co-Diagnostics technology drives the higher sensitivity and specificity of the self-administered CRL Rapid Response test.

Key Points: 
  • According to CRL's announcement , Co-Diagnostics technology drives the higher sensitivity and specificity of the self-administered CRL Rapid Response test.
  • CRL is one of the largest privately held clinical testing laboratories in the U.S., with dedicated facilities in North America and Europe.
  • Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology.
  • The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA).

MDxHealth Announces Results of Special and Extraordinary General Shareholders' Meetings

Thursday, July 30, 2020 - 4:00pm

Press releaseRegulated information 30 July 2020, 17:00 CEST

Key Points: 
  • Press releaseRegulated information 30 July 2020, 17:00 CEST
    IRVINE, CA, and HERSTAL, BELGIUM 30 July 2020 MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, today held a special general shareholders' meeting ("SGM") and an extraordinary general shareholders' meeting ("EGM").
  • The minutes of the SGM and EGM as well as the documents that were submitted to the meetings can be accessed via the Companys website.
  • MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.
  • For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth , facebook.com/mdxhealth and linkedin.com/company/mdxhealth .

Roche launches cobas prime Pre-analytical System, a first-of-its-kind solution designed to automate all common manual steps in molecular diagnostics laboratories

Thursday, July 30, 2020 - 6:05am

Molecular laboratories are seeking to automate, standardise and connect molecular testing as much as possible in order to address increasing testing demand.

Key Points: 
  • Molecular laboratories are seeking to automate, standardise and connect molecular testing as much as possible in order to address increasing testing demand.
  • The cobas prime Pre-analytical System enables a complete end-to-end solution for testing consolidation to help them achieve that goal.
  • Other solutions from Roche for testing consolidation and connectivity in molecular laboratories include the cobas 6800 and 8800 Systems, the cobas infinity laboratory solution, and a broad and expanding menu of assays.
  • The cobas prime Pre-analytical System is designed to automate all common pre-analytic steps seen in a molecular diagnostics laboratory, including vortexing, decapping, aliquoting, barcode labeling, reagent addition and heating.

Roche launches cobas prime Pre-analytical System, a first-of-its-kind solution designed to automate all common manual steps in molecular diagnostics laboratories

Thursday, July 30, 2020 - 6:05am

Molecular laboratories are seeking to automate, standardise and connect molecular testing as much as possible in order to address increasing testing demand.

Key Points: 
  • Molecular laboratories are seeking to automate, standardise and connect molecular testing as much as possible in order to address increasing testing demand.
  • The cobas prime Pre-analytical System enables a complete end-to-end solution for testing consolidation to help them achieve that goal.
  • Other solutions from Roche for testing consolidation and connectivity in molecular laboratories include the cobas 6800 and 8800 Systems, the cobas infinity laboratory solution, and a broad and expanding menu of assays.
  • The cobas prime Pre-analytical System is designed to automate all common pre-analytic steps seen in a molecular diagnostics laboratory, including vortexing, decapping, aliquoting, barcode labeling, reagent addition and heating.

Scientists Strive to Diagnose Illnesses Before Symptoms Appear

Wednesday, July 29, 2020 - 3:30pm

There are also various types of diagnostic methods including In VitroDiagnostics (IVD), Point Of Care (POC), Molecular diagnostics, genomic diagnosticsand others.

Key Points: 
  • There are also various types of diagnostic methods including In VitroDiagnostics (IVD), Point Of Care (POC), Molecular diagnostics, genomic diagnosticsand others.
  • In addition, cancer research organizations, along with public and private entities, are investing heavily in research projects to launch new, advanced diagnostic tools, which are capable of diagnoses significantly before the symptoms appear.
  • Overall, according to Grand View Research, Inc., the global cancer diagnostics market size was valued at USD 144.
  • "We are honored to have achieved this milestone, which demonstrates the market-wide acceptance of our products.

Scientists Strive to Diagnose Illnesses Before Symptoms Appear

Wednesday, July 29, 2020 - 3:30pm

There are also various types of diagnostic methods including In VitroDiagnostics (IVD), Point Of Care (POC), Molecular diagnostics, genomic diagnosticsand others.

Key Points: 
  • There are also various types of diagnostic methods including In VitroDiagnostics (IVD), Point Of Care (POC), Molecular diagnostics, genomic diagnosticsand others.
  • In addition, cancer research organizations, along with public and private entities, are investing heavily in research projects to launch new, advanced diagnostic tools, which are capable of diagnoses significantly before the symptoms appear.
  • Overall, according to Grand View Research, Inc., the global cancer diagnostics market size was valued at USD 144.
  • "We are honored to have achieved this milestone, which demonstrates the market-wide acceptance of our products.

Biotheranostics to Present at the LifeSci Partners Summer Symposium

Monday, July 27, 2020 - 2:00pm

Biotheranostics, Inc. operates a CLIA-certified and CAP-accredited diagnostic laboratory in San Diego, California.

Key Points: 
  • Biotheranostics, Inc. operates a CLIA-certified and CAP-accredited diagnostic laboratory in San Diego, California.
  • Biotheranostics, Inc., is a leading healthcare provider in the oncology field assisting physicians in the treatment of cancer patients.
  • Its suite of commercially available proprietary molecular diagnostic tests provides important information to physicians to tailor treatment to individual patients.
  • CancerTYPE ID is able to classify 50 cancer types and subtypes, representing more than 95 percent of all solid tumors based on incidence.

Global Genetic Counseling Market (2019 to 2030) - Featuring Ancestry, Arup Laboratories & Biron Health Group Among Others - ResearchAndMarkets.com

Monday, July 27, 2020 - 10:27am

According to this report the global genetic counseling market was valued at $972.2 million in 2019 and is anticipated to grow over $4,079.3 million by 2030.

Key Points: 
  • According to this report the global genetic counseling market was valued at $972.2 million in 2019 and is anticipated to grow over $4,079.3 million by 2030.
  • The global genetic counseling market is expected to grow at a double-digit compound annual growth rate in the forecast period 2020-2030, aided primarily by the impressive growth in the molecular diagnostics market.
  • However, with the advent of new players in the genetic counseling market, pharmacogenomic services and diagnostic counseling services have become an eminent part of current diagnostic and treatment practices.
  • Additionally, the increasing number of genetic counselors in both industry and hospital settings is also one of the key driving factors for the genetic counseling market.

Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.

Wednesday, July 22, 2020 - 12:05pm

Additionally, Dr. Skovronsky was appointed to the Research and Product Innovation Committee of Myriads Board.

Key Points: 
  • Additionally, Dr. Skovronsky was appointed to the Research and Product Innovation Committee of Myriads Board.
  • Dr. Skovronsky received his M.D., Ph.D. from University of Pennsylvania where he also completed sub-specialty training in neuropathology.
  • We are honored to welcome Dr. Skovronsky to the Myriad Board, said Louise Phanstiel, Chair of the Board of Myriad.
  • Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.